Navigation Links
United Therapeutics Corporation Reports Second Quarter 2011 Financial Results
Date:7/28/2011

SILVER SPRING, Md., July 28, 2011 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) today announced its financial results for the quarter ended June 30, 2011.

"I'm pleased with the successful unblinding of the FREEDOM-M study this quarter, as well as the very good operating results we achieved," remarked Martine Rothblatt, Ph.D., United Therapeutics' Chairman and Chief Executive Officer. "We remain on track to reach our 2011 forecast for revenues of $750 million, with a plus/minus margin of 5 percent."Total revenues for the quarter ended June 30, 2011 were $183.8 million, up from $134.7 million for the quarter ended June 30, 2010. Net income for the quarter ended June 30, 2011, was $73.9 million, or $1.27 per basic share, compared to $37.7 million, or $0.67 per basic share, for the same quarter in 2010. Gross margin from sales was $162.4 million for the quarter ended June 30, 2011, compared to $119.2 million for the same quarter last year. Earnings before non-cash charges(1) for the quarter ended June 30, 2011 were $93.5 million, compared to $65.7 million for the quarter ended June 30, 2010.

Results for the three- and six-month periods ended June 30, 2011 and June 30, 2010 do not include the results of Medicomp, Inc., our former telemedicine subsidiary, which we sold during the first quarter of 2011. The results of Medicomp, Inc. have been reported within discontinued operations on our consolidated statements of operations below.

(1) See definition of earnings before non-cash charges, a non-GAAP financial measure, and a reconciliation of net income to earnings before non-cash charges below.

Financial Results for the Three Months Ended June 30, 2011Revenues

The table below summarizes the components of net revenues (dollars in thousands):Three Months EndedJune 30,20112010Percentage ChangeCardiopulmonary products:Remodulin


'/>"/>

SOURCE United Therapeutics Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Advisory Panel Unanimously Recommends Approval of EXCOR(R) Pediatric Ventricular Assist Device for Use in the United States
2. Daiichi Sankyo Selects Veeva CRM to Support Customer Engagement Initiatives in the United Kingdom
3. United Therapeutics Corporation To Announce Second Quarter 2011 Financial Results Before Market Open on Thursday, July 28, 2011
4. United Therapeutics Corporation Completes Enrollment of FREEDOM-C(2) Trial
5. United Therapeutics Corporation Reports 2010 Fourth Quarter and Annual Financial Results
6. United Therapeutics Corporation to Announce Fourth Quarter and Annual 2010 Financial Results Before Market Open on Tuesday, February 15, 2011
7. United Therapeutics Corporation Reports Third Quarter 2010 Financial Results
8. United Therapeutics Corporation to Announce Third Quarter 2010 Financial Results Before Market Open on Thursday, October 28, 2010
9. Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
10. United Therapeutics Corporation to Announce Second Quarter 2010 Financial Results Before Market Open on Wednesday, July 28, 2010
11. Report Details How States Respond to Citizens United Decision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... 02, 2015 Global Stem ... alliance with Shenzhen HANK Bioengineering Co., Ltd. and ... alliance will establish a stem cells training course ... in September 2015. , Shenzhen HANK is a ... award-winning scientist, microbiologist and virologist, to integrate research, ...
(Date:3/1/2015)... Market Publishers Ltd and DataGroup Booksellers ... promotion on Internet. MarketPublishers.com is now authorised to ... DataGroup Booksellers. , Natalie Aster, Assistant Manager at ... the recent partnership agreement as follows: “We are ... of publishers. Since 1974, the company has been ...
(Date:2/27/2015)... Immunovaccine Inc. (“Immunovaccine” or the “Company”) ... press release disseminated this morning by PR Web, and ... press release states that Immunovaccine has entered into a ... release did not originate from Immunovaccine and there is ... release. Please note that all official statements by ...
(Date:2/27/2015)... , Feb. 27, 2015  Pharmacyclics, Inc. ... longer-term toxicology studies for its newly developed Bruton,s ... RA, have been completed. The results of these ... Food and Drug Administration. The feedback received from ... the ongoing first-in-human study. Additional preclinical work is ...
Breaking Biology Technology:Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 2Market Publishers Ltd and DataGroup Booksellers Sign Partnership Agreement 3Immunovaccine Disclaims Hoax Press Release 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3
... Higher Prevalence ... BARCELONA, Spain, May 25 In a first-of-its-kind study,in ... and,Australia reported having one or more bone fractures since the ... risk for a fracture, only 26%,reported use of bone-saving drugs, ...
... /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a,vaccine development ... one of Pennsylvania,s Best 50 Women in Business. ... received the honors,from Pennsylvania Governor Edward G. Rendell., ... industry. Her clinical work in,antigen discovery for ovarian ...
... BioTrends Research Group, Inc.,released Wave 1 of ... syndicated market research project tracking the launch of,Renvela ... of product,availability. The baseline report was published in ... one month post Renvela launch, and provides,quantitative information ...
Cached Biology Technology:Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 2Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 3Global Study Reveals Differences in Standard of Care for Osteoporosis Across the World 4ImmunoVaccine Technologies Congratulates Dr. Ramila Philip as One of PA's Best 50 Women in Business 2Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected 2
(Date:2/24/2015)... , Feb. 24, 2015 Research and Markets ... addition of the "Global 2D Gesture Recognition ... The analysts forecast the Global 2D ... of 32.12% over the period 2014-2019 ... non-traditional sectors is one of the major trends ...
(Date:2/18/2015)... , Feb. 18, 2015  Cepheid (NASDAQ: CPHD ... the following conferences, and invited investors to participate via webcast. ... Boston, MA Tuesday, March 3, 2015 at 11.20 ... Orlando, FL Wednesday, March 4, 2015 ... To access the live webcasts for these events, please visit ...
(Date:2/12/2015)... Conn. , Feb. 12, 2015 NXT-ID, ... or the "Company"), a biometric authentication company focused on ... has filed provisional patent 62/113114 for DISTRIBUTED ... DEVICES. The patent further establishes NXT-ID,s position ... its intellectual property portfolio the ability for multiple devices ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3
... Danish research team leads the way for future biodiversity ... of threatened wildlife a lake water sample the size ... fauna. Global biodiversity is plummeting while biologists are ... remains a major challenge. The biologist toolset has changed little ...
... 17, 2011   Life Technologies Corporation ... the company has introduced its GeneArt® Algae Engineering ... expression systems for photosynthetic microalgae Chlamydomonas reinhardtii ... are model organisms for the study of photosynthesis, ...
... biological data from electronic tags, ear bone microchemistry and fisheries ... side of the Atlantic influences the other side. Bluefin ... precipitously since 1950, according to the study published today in ... model estimates the number of Atlantic bluefin tuna remaining in ...
Cached Biology News:A lake fauna in a shot-glass 2GeneArt® Algae Engineering Kits by Life Technologies™ 2GeneArt® Algae Engineering Kits by Life Technologies™ 3New study provides comprehensive view of the status of Atlantic bluefin tuna 2New study provides comprehensive view of the status of Atlantic bluefin tuna 3
Recombinant Ovine IFN Tau. Active on sheep, cow, human and mouse cells. Activity: 5.7 x 10 7 u/mg...
... the easiest to program twin-strip microplate ... liquid level sensors for wash, waste ... shaker and automatic rinsing and priming ... big bottle model is designed for ...
The Wellwash 4 Mk 2 combines high performance and flexibility with reliability, simplicity and ease of use. This advanced microplate washer meets the exacting standards of today's assay requirements....
... handy dispensers save space and organize ... other garb. They are the perfect ... used in labs, processing and manufacturing. ... and the particles they attract. Many ...
Biology Products: